Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein
Kailu Yang, Chuchu Wang, Alex J.B. Kreutzberger, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 40
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
Liyan Guo, Sheng Lin, Zimin Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 48
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3664-3702
Open Access | Times Cited: 28
Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity
Saïd Mougari, Valérie Favède, Camilla Predella, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Fatty acid binding protein 5 inhibitors as novel anticancer agents against metastatic castration-resistant prostate cancer
Hehe Wang, Chuanzhou Zhu, Manojit Mosur Swamynathan, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 122, pp. 118136-118136
Closed Access | Times Cited: 1
Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides
Yue Hu, Yuanmei Zhu, Yanying Yu, et al.
Antiviral Research (2023) Vol. 212, pp. 105571-105571
Open Access | Times Cited: 18
Ultrafast universal fabrication of configurable porous silicone-based elastomers by Joule heating chemistry
Feng Xu, Hongjian Zhang, Haodong Liu, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 11
Open Access | Times Cited: 7
Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
Yang Li, Si-Ming Lu, Jia-Long Wang, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33179-e33179
Open Access | Times Cited: 6
A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery
Lili Wu, Anqi Zheng, Yangming Tang, et al.
Science China Life Sciences (2023) Vol. 66, Iss. 10, pp. 2201-2213
Closed Access | Times Cited: 15
Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus
Mingxing Tang, Xin Zhang, Yanhong Huang, et al.
Frontiers in Microbiology (2023) Vol. 13
Open Access | Times Cited: 11
Fatty Acid Binding Protein 5 Inhibitors as Novel Anticancer Agents Against Metastatic Castration-Resistant Prostate Cancer
Iwao Ojima, Hehe Wang, Chuanzhou Zhu, et al.
(2025)
Closed Access
Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development
Ariel J. Kuhn, Victor K. Outlaw, Tara C. Marcink, et al.
Journal of Virology (2025)
Open Access
Capture of fusion-intermediate conformations of SARS-CoV-2 spike requires receptor binding and cleavage at either the S1/S2 or S2’ site
Sabrina Lusvarghi, Russell Vassell, Brittany Williams, et al.
PLoS Pathogens (2025) Vol. 21, Iss. 4, pp. e1012808-e1012808
Open Access
Evolution of a Distinct SARS-CoV-2 Lineage Identified during an Investigation of a Hospital Outbreak
Hosoon Choi, Munok Hwang, Lisa Cornelius, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 337-337
Open Access | Times Cited: 3
Design of Flavonoid‐Based Lipid Domains as Fusion Inhibitors to Efficiently Block Coronavirus and Other Enveloped Virus Infection
Nikesh Dewangan, Indrani Das Jana, Sandeep Yadav, et al.
Small (2025)
Closed Access
Adaptive variations in SARS-CoV-2 spike proteins: effects on distinct virus-cell entry stages
Enya Qing, Tom Gallagher
mBio (2023)
Open Access | Times Cited: 9
Cholesterol and Ceramide Facilitate Membrane Fusion Mediated by the Fusion Peptide of the SARS-CoV-2 Spike Protein
Kristina Niort, Julia Dancourt, Erwan Boedec, et al.
ACS Omega (2023) Vol. 8, Iss. 36, pp. 32729-32739
Open Access | Times Cited: 9
Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor
Kailu Yang, Chuchu Wang, Alex J.B. Kreutzberger, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 13
Open Access | Times Cited: 5
SARS-CoV-2 inhibitory activity of a short peptide derived from internal fusion peptide of S2 subunit of spike glycoprotein
Maria Alfreda Stincarelli, Michael Quagliata, Andrea Di Santo, et al.
Virus Research (2023) Vol. 334, pp. 199170-199170
Open Access | Times Cited: 5
SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization
Enya Qing, Julisa Salgado, Alexandria Wilcox, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 12, pp. e1012757-e1012757
Open Access | Times Cited: 1
Investigating vulnerability of the conserved SARS-CoV-2 spike's heptad repeat 2 as target for fusion inhibitors using chimeric miniproteins
Daniel Polo-Megías, Mario Cano‐Muñoz, Alberto G. Berruezo, et al.
International Journal of Biological Macromolecules (2024) Vol. 262, pp. 130132-130132
Open Access | Times Cited: 1
Blood pH Analysis in Combination with Molecular Medical Tools in Relation to COVID-19 Symptoms
Hans‐Christian Siebert, Thomas Eckert, Anirban Bhunia, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1421-1421
Open Access | Times Cited: 3
Efficient inhibition of SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants by fusion inhibitor HY3000 peptide
Lili Wu, Anqi Zheng, Yangming Tang, et al.
hLife (2023) Vol. 2, Iss. 1, pp. 43-46
Open Access | Times Cited: 3
Reaching the Final Endgame for Constant Waves of COVID-19
Norman A. Ratcliffe, Helena Carla Castro, Marcelo Salabert Gonzalez, et al.
Viruses (2022) Vol. 14, Iss. 12, pp. 2637-2637
Open Access | Times Cited: 5
Towards developing a variant-proof SARS-CoV-2 vaccine
Hua Peng, Yang‐Xin Fu
Cell Research (2023) Vol. 33, Iss. 1, pp. 5-6
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top